Retatrutide 30 mg
Latest certified batch RT30-26-03GLP-1 / GIP / glucagon
VAT included. Delivery €NaN flat.
This listing is not currently available to order.
| Molecular target | GLP-1GIPGlucagon |
|---|---|
| Molecular class | Acylated linear peptide |
| Product grade | Research grade |
| Format | Lyophilised powder, sealed vial |
| Vial content | 30 mg |
Single-vial pricing
| Purity, HPLC (area %), mean of 2 vials | 99.636% |
|---|---|
| Measured content, per vial, mean of 2 vials | 29.92 mg |
| Vials assayed | 2 |
| Laboratory | Janoshik Analytical |
| Assayed | 7 Apr 2026 |
The certificate for batch RT30-26-03, as Janoshik Analytical issued it. Contact details, the laboratory's reference and its code are masked. More on the certificates
Every batch we ship assays at 98.0% or higher by RP-HPLC and holds 90% of its labelled mass or more, or we refund the order and the cost of the test. How the guarantee works
Specification and appearance
Storage and stability
- 2–8 °C, sealed and unopened — months.
- Keep dry and in the dark; UV degrades peptides fastest.
- −20 °C or below for long-term storage — years. Avoid repeated freeze–thaw cycles.
Batch archive
Every batch of this vial an independent laboratory has certified, so material already in storage stays traceable to the certificate it was released against.
- Batch RT30-26-03 — analysed 7 Apr 2026 — 99.636% — current
- Batch RT30-2026-02 — analysed 24 Feb 2026 — 99.478% — certificate
- Batch RT30-01-26 — analysed 26 Jan 2026 — 99.496% — certificate
- Batch 89478 — analysed 5 Dec 2025 — certificate
- Batch 89476 — analysed 21 Nov 2025 — certificate
Selected literature
A neutral bibliography for this molecule. Purivor makes no statement about what these papers say — the citations are provided so you can read the primary sources yourself.
- Coskun T. et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist: from discovery to clinical proof of concept. Molecular Metabolism, 18, 3–14. DOI 10.1016/j.molmet.2018.09.009
- Willard F. S. et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5(17), e140532. DOI 10.1172/jci.insight.140532